Related Experiment Video
Updated: Feb 10, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer
Dong Guo1,2, Jinbao Zhang1, Wang Jing2,3
1Weifang Medical University, Weifang, PR China.
Aim:
We aimed to investigate the association between systemic immune-inflammation index (SII) and the clinical outcomes in patients with advanced non-small-cell lung cancer.
Materials & Methods:
The SII was calculated as platelet (P) × neutrophil (N)/lymphocyte (L), and the data were obtained within 1 week before treatment. Kaplan-Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII.
Results:
Kaplan-Meier analyses revealed that the higher SII group was associated with poorer progression-free survival (p < 0.001) and poorer overall survival (p < 0.001). Multivariable Cox analysis further revealed SII as an independent prognostic factor for overall survival (p = 0.010) and progression-free survival (p = 0.001).
Conclusion:
SII can serve as a useful biomarker to predict recurrence and death for patients with advanced non-small-cell lung cancer.
Related Concept Videos
Inflammation
What is the Immune System?
Lung Capacity
Cell-mediated Immune Responses
Cells of the Adaptive Immune Response
Humoral Immune Responses

